ArticleCell reports2023
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.Blood advances · 2023Pooled it
- Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology · 2024Trial
- Variant-specific spike conformational dynamics shape memory B cell selection during recall.bioRxiv : the preprint server for biology · 2026Article
- Article
- Cryo-ET of IgG bivalent binding on SARS-CoV-2 provides structural basis for antibody avidity.Nature communications · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332Nature immunology · 2026Article
- Review
- IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of a broad and potent V3 glycan site bNAb targeting an N332bioRxiv : the preprint server for biology · 2025Article
- Review
- A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.Cell reports · 2025Article
- Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection.Communications biology · 2025Article
- The molecular reach of antibodies crucially underpins their viral neutralisation capacity.Nature communications · 2025Article
- Competitive Epitope Binning Using HT-SPR.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.Nature communications · 2024Article
- Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.PLoS pathogens · 2024Article
- Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 18 institutions in 4 countries.
Heather M CallawayCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Kathryn M HastieCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Sharon L SchendelCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Haoyang LiCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Xiaoying YuCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Jeremy ShekCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Tierra BuckCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Sean HuiCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Dan BedingerCarterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA.
Camille TroupCarterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA.
S Moses DennisonCenter for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
Kan LiCenter for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
Michael D AlpertEmmune, Inc., 14155 US Highway 1, Juno Beach, FL 33408, USA.
Charles C BaileyEmmune, Inc., 14155 US Highway 1, Juno Beach, FL 33408, USA.
Sharon BenzenoAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Jody L BonnevierBio-techne, 614 McKinley Place NE, Minneapolis, MN 55413, USA.
Jin-Qiu ChenACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA.
Charm ChenACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA.
Hyeseon ChoAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Peter D CromptonAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Vincent DussuptEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Kevin C EntzmingerAbwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA.
Yassine EzzyatJounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA.
Jonathan K FlemingAbwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA.
Nick GeukensPharmAbs, The KU Leuven Antibody Center, KU Leuven, 3000 Leuven, Belgium.
Amy E GilbertAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Yongjun GuanAntibody BioPharm, Inc., 401 Professional Dr Ste 241, Gaithersburg, MD 20879, USA; Shanghai Life Technology Co., Ltd., 781 Cai Lun Rd, Ste 801, Pudong, Shanghai 201203, China.
Xiaojian HanDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Christopher J HarveyJounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA; Phenomic AI, 661 University Avenue, Suite 1300 MaRS Centre, West Tower, Toronto, ON M5G 0B7, Canada.
Julia M HatlerBio-techne, 614 McKinley Place NE, Minneapolis, MN 55413, USA.
Bryan HowieAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Chao HuDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Ailong HuangKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Maya ImbrechtsPharmAbs, The KU Leuven Antibody Center, KU Leuven, 3000 Leuven, Belgium.
Aishun JinDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Nik KamachiACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA.
Gladys KeitanyAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Mark KlingerAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Jay K KollsTulane School of Medicine, Center for Translational Research in Infection and Inflammation, New Orleans, LA 70112, USA.
Shelly J KrebsEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Tingting LiDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Feiyan LuoDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Toshiaki MaruyamaAbwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA.
Michael A MeehlJounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA.
Letzibeth Mendez-RiveraEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Andrea MusaAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
C J OkumuraAbwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA.
Benjamin E R RubinAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Aaron K SatoTwist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
Meiying ShenDepartment of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Anirudh SinghJounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA.
Shuyi SongDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Joshua TanAntibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Jeffrey M TrimarchiEmmune, Inc., 14155 US Highway 1, Juno Beach, FL 33408, USA; Department of Biological Sciences, Lehigh University, 111 Research Drive, Bethlehem, PA 18015, USA.
Dhruvkumar P UpadhyayJounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA; Amgen, Inc., 360 Binney St., Cambridge, MA 02141, USA.
Yingming WangDepartment of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.
Lei YuGuangzhou Eighth People's Hospital & Guangzhou Medical University, Guangzhou 510060, China.
Tom Z YuanTwist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
Erik YuskoAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA.
Bjoern PetersCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92039, USA.
Georgia TomarasCenter for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92039, USA. Electronic address: erica@lji.org.
La Jolla Institute for Immunology · USAdaptive Biotechnologies (United States) · USChongqing Medical University · CNDuke University · USHenry M. Jackson Foundation · USNational Institutes of Health · USCarterra (United States) · USEmmune (United States) · USKU Leuven · BER&D Systems (United States) · USTwist Bioscience (United States) · USBiogen (United States) · USGuangzhou Eighth People's Hospital · CNIntegrated BioTherapeutics (United States) · USLehigh University · USMemorial Medical Center · USThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNTulane University · US
Funding
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI DIAMOND, MICHAEL S · 2019 to 2023
$40.0MDevelopment of AAV vectors for long-term expression of eCD4-IgR44AI134269 · NIAID · EMMUNE, INC · PI ALPERT, MICHAEL DAVID, FARZAN, MICHAEL R. · 2017 to 2020
$3.3MImproving the pharmacokinetics, potency, and immunogenicity of eCD4-IgR44AI145491 · NIAID · EMMUNE, INC · PI ALPERT, MICHAEL DAVID · 2019 to 2022
$3.0MNIAID NIH HHS R44 AI134269NIAID NIH HHS R44 AI145491NIAID NIH HHS U19 AI142790
Abstract
The SARS-CoV-2 Omicron variant of concern (VoC) and its sublineages contain 31-36 mutations in spike and escape neutralization by most therapeutic antibodies. In a pseudovirus neutralization assay, 66 of the nearly 400 candidate therapeutics in the Coronavirus Immunotherapeutic Consortium (CoVIC) panel neutralize Omicron and multiple Omicron sublineages. Among natural immunoglobulin Gs (IgGs), especially those in the receptor-binding domain (RBD)-2 epitope community, nearly all Omicron neutralizers recognize spike bivalently, with both antigen-binding fragments (Fabs) simultaneously engaging adjacent RBDs on the same spike. Most IgGs that do not neutralize Omicron bind either entirely monovalently or have some (22%-50%) monovalent occupancy. Cleavage of bivalent-binding IgGs to Fabs abolishes neutralization and binding affinity, with disproportionate loss of activity against Omicron pseudovirus and spike. These results suggest that VoC-resistant antibodies overcome mutagenic substitution via avidity. Hence, vaccine strategies targeting future SARS-CoV-2 variants should consider epitope display with spacing and organization identical to trimeric spike.
Indexed as
COVID-19Antibodies, NeutralizingAntibodies, ViralEpitopesEthnicityHumansNeutralization TestsSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralEpitopesbivalent antibody bindingcoronavirusCOVID-19CP: ImmunologyneutralizationSARS-CoV-2therapeutic antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.